EU Notified Body (BSI Netherlands) and the EMA Grant Approval of the LeukoStrat® CDx FLT3 Mutation Assay for VANFLYTA® Therapy in the EU and EEA
Invivoscribe is excited to announce that their CE-2797 IVD certified LeukoStrat® CDx FLT3 Mutation Assayhas been approved by BSI (Netherlands) and the EMA to aid in the selection of individuals in the European Union and European Economic Area with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML) who may be eligible to receive treatment with Daiichi Sankyo’s VANFLYTA® (quizartinib). BSI, a Notified Body accredited in the EU, is authorized to assess and certify In-Vitro Diagnostics (IVDs), ensuring product compliance with European directives and regulations.
Invivoscribe continues to lead the way in developing standardized diagnostic tools that enable tailored treatment strategies, ultimately aiming to enhance the quality of life for individuals battling this aggressive form of leukemia.
“Targeting driver mutations linked to new therapies such as VANFLYTA®, is key to improving the lives of AML patients,” said Jason Gerhold, Invivoscribe’s V.P. of Global Regulatory, Quality and Clinical Affairs. “Invivoscribe’s Class C CDx assay is now approved by BSI as a CE-marked IVD, offering oncologists another tool to ensure that their patients are provided optimal treatments.”
AML is a blood cancer characterized by the rapid growth of abnormal white blood cells1 and has the lowest 5-year survival rate (31.9%) among people diagnosed with leukemia.2 About 25% of AML patients have a FLT3-ITD mutation, which contributes to the growth and survival of cancer cells and is associated with a poor prognosis.3
EU Intended Use
The LeukoStrat® CDx FLT3 Mutation Assay is a PCR-based in vitro diagnostic test designed to detect internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations D835 and I836 in the FLT3 gene in genomic DNA extracted from mononuclear cells obtained from peripheral blood or bone marrow aspirates of patients diagnosed with acute myelogenous leukemia (AML). The LeukoStrat CDx FLT3 Mutation Assay may be used as a companion diagnostic for the following therapeutic:
In regions where XOSPATA® (gilteritinib fumarate) is available, the LeukoStrat CDx FLT3 Mutation Assay is used as an aid in the assessment of patients with AML for whom XOSPATA® (gilteritinib fumarate) treatment is being considered.
In regions where VANFLYTA® (quizartinib hydrochloride) is available, the LeukoStrat CDx FLT3 Mutation Assay is used as an aid in the assessment of patients with FLT3-ITD+ AML for whom VANFLYTA® (quizartinib hydrochloride) treatment is being considered.
The qualitative, non-automated test is for use on the 3500xL or 3500xL Dx Genetic Analyzers.
About Invivoscribe
Invivoscribe is a global, vertically-integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics®. For nearly thirty years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality standardized reagents, tests, bioinformatics tools, and services to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with global pharmaceutical companies, providing expertise in diagnostic development and regulatory submission through commercialization of companion diagnostics. For additional information, please visit www.invivoscribe.com or contact us at inquiry@invivoscribe.com and follow us on LinkedIn.
1https://www.cancer.net/cancer-types/leukemia-acute-myeloid-aml/introduction
2https://seer.cancer.gov/statfacts/html/amyl.html. Accessed 12 August 2024.
3 Daver N et al. Leukemia (2019) 33:299–312.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241008859935/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Reports First Quarter 2025 Results6.5.2025 22:35:00 CEST | Press release
IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2025. Management Commentary “IFF delivered solid first quarter results, driven by disciplined execution and broad-based growth across most of our business,” said IFF CEO Erik Fyrwald. “Our growth, combined with ongoing productivity initiatives, contributed to a meaningful increase in profitability. We also successfully completed the divestiture of our Pharma Solutions business two months ahead of schedule, a key milestone that supports the achievement of our targeted debt leverage ratio." “As we navigate the heightened macroeconomic uncertainty in today’s environment, we remain focused on what we can control - collaborating with our customers to drive growth, investing in innovation and delivering increased productivity. We are maintaining our full-year financial guidance ranges but recognize that the uncertain environment has potential for more challenges, yet we remain confident in our long-term strategy
Lattice to Showcase Advanced Edge AI Solutions at New-Tech 2025 Exhibition6.5.2025 22:00:00 CEST | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it will showcase its latest FPGA technology at the New-Tech 2025 Exhibition. Lattice technology demos will be featured in the Telsys Ltd. booth, showcasing industry-leading low power, small form factor FPGAs and application-specific solutions enabling advanced embedded vision, artificial intelligence, and sensor fusion capabilities. Additionally, Lattice will deliver a technical presentation titled “Power-Efficient Robotics and Automation Fueled by Lattice FPGA Technology” about how advanced, power-optimized FPGAs can dramatically reduce power consumption for next-generation automation and robotics solutions for Industrial applications. Who: Lattice Semiconductor What / When: May 20 – 21: Lattice demo showcase (Telsys Ltd. Booth #67-68) May 21, 10:20 a.m.: “Power-Efficient Robotics and Automation Fueled by Lattice Semiconductor FPGA Technology” technical presentation Where: New-Tech 2025 Exhib
Rockstar Games Releases Trailer 2 for Grand Theft Auto VI6.5.2025 18:37:00 CEST | Press release
Explore Vice City and beyond at rockstargames.com/VI Rockstar Games®, a publishing label of Take-Two Interactive Software, Inc. (NASDAQ: TTWO), is proud to announce the release of Trailer 2 for Grand Theft Auto VI, alongside a closer look at the biggest, most immersive evolution of the series yet: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250506495901/en/ Set to launch on May 26, 2026, on PlayStation® 5 computer entertainment systems and Xbox Series X|S games and entertainment systems, Grand Theft Auto VI will soon be available for wishlisting on both the PlayStation and Microsoft Stores. Vice City, USA. Jason and Lucia have always known the deck is stacked against them. But when an easy score goes wrong, they find themselves on the darkest side of the sunniest place in America, in the middle of a criminal conspiracy stretching across the state of Leonida — forced to rely on each other more than ever if they want to mak
Monroe Capital, SMBC and MA Financial Launch US$1.7 Billion Middle Market Lending Joint Venture6.5.2025 16:07:00 CEST | Press release
Monroe Capital, Sumitomo Mitsui Banking Corporation (SMBC) and MA Asset Management (part of MA Financial Group, ASX: MAF) today announced the formation of a new joint venture (“JV”), which will invest up to US$1.7 billion in senior secured loans to U.S. middle market borrowers. The JV harnesses the complementary capabilities of the three partnering institutions to establish a differentiated platform focused on the attractive middle market subset of private credit. The JV expects to benefit from broad access to high-quality, proprietary deal flow of first-lien senior-secured loans to established middle market companies, leveraging the loan origination capabilities of Monroe Capital’s direct lending infrastructure, SMBC’s established private credit and sponsor finance platform and MA Financial’s expertise in specialty credit and co-lending. The JV’s investable capital will be provided by Monroe Capital, SMBC and MA Financial (via its managed funds). Monroe Capital is one of the largest l
Sentry Acquires Emerge Tools to Help Developers Ship Better, Faster Mobile Apps6.5.2025 15:00:00 CEST | Press release
Emerge’s suite of tools will help Sentry build the most complete mobile app monitoring solution on the market Sentry, the leading debugging platform for developers, today announced it has acquired Emerge Tools, a prominent provider of mobile app development solutions. Emerge Tools enables teams to deliver smaller, faster and more reliable mobile apps. Its platform powers visual regression testing at OpenAI and app size monitoring at Spotify. Companies like DoorDash have used Emerge to improve app launch speed by 60%, while Duolingo used Emerge to help delete thousands of lines of unnecessary code. According to Statista, “mobile applications are projected to generate more than 613 billion dollars in revenue in 2025”. In a fast growing mobile app landscape, slow loading times, excessive battery drain, and UI instability can lead to negative user sentiment and app abandonment. Emerge Tools directly addresses these challenges by giving developers the ability to proactively identify and res
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom